| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
The pathological findings of the murine models of pulmonary hypertenion was demonstated to be suppressed by treatment with an antagonist of thrombin receptor PAR1 and knockout of PAR1 gene. In both cases, the vascular proliferative lesions and right ventricular hypertrophy were ameliorated. Furthermore, the expression of thrombin receptor PAR1 in pulmonary arteries was found to be up-regulated. The receptor upregulation is suggested to contribute to development of pathophysiology. The present study propose a potential of thrombin receptor PAR1 antagonist to serve as a novel therapeutic agent for the treatment of pulmonary hypertension.
|
